Search

Displaying results 3661 - 3670 of 6951 in total
  1. Drug

    Entacapone

    go.drugbank.com/drugs/DB00494
    ApprovedInvestigational

    Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols.

  2. Drug

    Esterified estrogens

    go.drugbank.com/drugs/DB09381
    Approved

    It is being also for the prevention and treatment of osteoporosis.

  3. Drug

    Triprolidine

    go.drugbank.com/drugs/DB00427
    Approved

    First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.

    Categories: Antihistamines for Systemic Use
  4. Drug

    Oxacillin

    go.drugbank.com/drugs/DB00713
    ApprovedInvestigational

    An antibiotic similar to flucloxacillin used in resistant staphylococci infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Tolcapone

    go.drugbank.com/drugs/DB00323
    ApprovedInvestigationalWithdrawn

    Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline ...

  6. Drug

    Pegaptanib

    go.drugbank.com/drugs/DB04895
    ApprovedWithdrawn

    Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.

  7. Target

    P2Y purinoceptor 12

    go.drugbank.com/bio_entities/BE0000110
    TargetHumans

    Receptor for ADP and ATP coupled to G proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation

    Synonyms: ADP-glucose receptor, P2Y12 platelet ADP receptorFunction: G protein-coupled adenosine receptor activity
  8. Drug

    Lifitegrast

    go.drugbank.com/drugs/DB11611
    ApprovedInvestigational

    Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome).

  9. Drug

    Sibutramine

    go.drugbank.com/drugs/DB01105
    ApprovedIllicitWithdrawn

    Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity.

  10. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC. … [A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases.